Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Public ClinicalTrials.gov record NCT01395914. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Study identification
- NCT ID
- NCT01395914
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Helsinn Therapeutics (U.S.), Inc
- Industry
- Enrollment
- 513 participants
Conditions and interventions
Conditions
Interventions
- Anamorelin HCl Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2011
- Primary completion
- May 31, 2014
- Completion
- Jan 31, 2015
- Last update posted
- Sep 13, 2017
2011 – 2015
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Corona | California | — | — |
| Not listed | Fountain Valley | California | — | — |
| Not listed | Fullerton | California | — | — |
| Not listed | Glendale | California | — | — |
| Not listed | La Jolla | California | — | — |
| Not listed | Riverside | California | — | — |
| Not listed | Washington D.C. | District of Columbia | — | — |
| Not listed | Orange City | Florida | — | — |
| Not listed | Quincy | Illinois | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Lake Success | New York | — | — |
| Not listed | Durham | North Carolina | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Sylvania | Ohio | — | — |
| Not listed | West Reading | Pennsylvania | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Falls Church | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01395914, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 13, 2017 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01395914 live on ClinicalTrials.gov.